SCHEMBL4585907

SCHEMBL4585907

CC(=O)N[C@@H](CSCC(=O)C(=O)OCCCO[N+](=O)[O-])C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.37
ALDH1A1 P00352 2/20 0.37
PTGS2 P35354 2/20 0.35
KDM4E B2RXH2 1/20 0.35
THRB P10828 1/20 0.35
ALOX15 P16050 1/20 0.35
NFKB1 P19838 1/20 0.35
THPO P40225 1/20 0.35
RECQL P46063 1/20 0.35
BLM P54132 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ICMT O60725 2/20 0.33
PPARG P37231 1/20 0.32
PPARA Q07869 1/20 0.32
ACE P12821 1/20 0.32
TLR2 O60603 1/20 0.31
ITGB3 P05106 1/20 0.31
ITGA2B P08514 1/20 0.31
CA12 O43570 1/20 0.30
CA1 P00915 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4586125 0.83 MAPT (0.37) MAPTALDH1A1PTGS2KDM4ETHRB
SCHEMBL4587971 0.82 ALDH1A1 (0.36) MAPTALDH1A1PTGS2KDM4ETHRB
SCHEMBL4959876 0.81 ITGB1 (0.37) MAPTALDH1A1PTGS2KDM4ETHRB
SCHEMBL4588021 0.81 MAPT (0.34) MAPTALDH1A1PTGS2KDM4ETHRB
SCHEMBL4587822 0.81 MAPT (0.36) MAPTALDH1A1PTGS2KDM4ETHRB
SCHEMBL4587129 0.80 MAPT (0.35) MAPTALDH1A1PTGS2KDM4ETHRB
SCHEMBL4586128 0.80 CA12 (0.35) PTGS2CA12CA1CA2CA4
SCHEMBL4588470 0.79 PPARA (0.42) ICMTPPARGPPARAACECA12
SCHEMBL4587072 0.79 MAPT (0.38) MAPTALDH1A1PTGS2KDM4ETHRB
SCHEMBL5133823 0.79 MAPT (0.37) MAPTALDH1A1PTGS2KDM4ETHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US claimed
EP-1692107-A4 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-10-29 EP claimed
EP-1692107-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2006-08-23 EP claimed
WO-2005060603-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-07-07 WO claimed
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use PC, PDK1, NOS3 MAPT 3734/4885ALDH1A1 567/4885PTGS2 177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.